Ispol'zovanie kliniko-ekonomicheskogo analiza v taktike obsledovaniya patsientov s ploskokletochnymi intraepitelial'nymi porazheniyami


Cite item

Full Text

Abstract

About the authors

L A Badalova

S I Rogovskaya

References

  1. Авксентьева М.В., П.А Воробьев, И.Б. Герасимов, С.Г. Горохова. Проект отраслевого стандарта «Фармакоэкономические исследования. Общие положения». Проблемы стандартизации в здравоохранении. 2000; 4.
  2. Бебнева Т.Н., Прилепская В.Н. Папилломавирусная инфекция и патология шейки матки. Гинекология. 2001; 1.
  3. Бусуек Г.П., Шагинян И.А., Александрова Г.А. и др. Эпидемиологические аспекты современной демографической ситуации в России Вестник. РАМН. 2005; 8.
  4. Воробьев П.А, Авксентьева М.В., Борисенко О.В. и др. Клинико-экономический анализ. М.: Ньюдиамед, 2008.
  5. Воробьев П.А., Авксентьева М.В., Юрьев А.С., Сура М.В. Клинико-экономический анализ. М.: Ньюдиамед, 2004.
  6. Королева Н.Ю. Разработка модели и оценка экономической эффективности скрининга рака шейки матки (на примере Тверской обл.). Дис. ... канд. мед. наук. М., 2007.
  7. Куевда Д.А., Шипулина О.Ю. ВПЧ-тестирование: алгоритмы диагностики и требования к молекулярным тестам для выявления вирусов папилломы человека. ФГУН Центральный НИИ Эпидемиологии Роспотребнадзора, Москва.
  8. Прилепская В.Н. Профилактика рака шейки матки: методы ранней диагностики и новые скрининговые технологии. Гинекология. 2007; 1 (9).
  9. Роговская С.И., Прилепская В.Н. Профилактика папилломавирусной инфекции и рака шейки матки. Гинекология. 2005; 1 (7).
  10. American Cancer Society Guidline for early detection of cervical neoplasia and cancer. CA Cancer O Clin 2002; 52: 342-62.
  11. ASCUS-LSIL Traige Study (ALTS) Group. A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations. Am J Obstet Gynecol 2003; 188: 1393.
  12. Austoker J. Cancer Prevention in Primary Care: Screening for cervical cancer BMJ 1994.
  13. Bosch FX, Lorincz A, Munoz N et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55: 244-65.
  14. Brisson M et al. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine 2007; 25: 5399-408.
  15. Carozzi F, Confortini M, Palma PD, Del Mistro , et al. Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. The Lancet Oncology 2008; 10 (9): 937-45.
  16. Cuzick J, Clavel C, Petry KU et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006; 119: 1095.
  17. Dallenbach-Hellweg G, Trunk MJ, Von Knebel Doeberitz M. Traditional and new molecular methods for early detection of cervical cancer. Arch Pathol 2004; 5: 35-9.
  18. Denny LA, Wright TC Jr. Human papillomavirus testing and screening. Best Pract Res Clin Obstet Gynaecol 2005; 19: 501.
  19. Elske van den Akker-van Marle, Marjolein van Ballegooijen, Gerrit J van Oortmarssen et al. Cost-Effectiveness of Cervical Cancer Screening: Comparison of Screening Policies. JNCI 2001; 3 (94): 193-204.
  20. Fahey MT, Irwig L, Macaskill P. Meta-anallysis of Pap-test accuracy. Am J Epidemiol 1995; 141: 680-9.
  21. Franco EL, Duarte-Franco E, Ferenczy A. Cervical cancer: epidemiology, prevention, and role of human papillomavirus infection. Can Med Assoc J 2001; 164: 1017-25.
  22. Goldie SJ, Kuhn L, Denny L et al. Policy analysis of cervical cancer screening strategie in lowresource settings: clinical benefits and costeffectiveness. J Am Med As 2001; 24: 285.
  23. Grace A, McBrearty P, Troost S et al. Comparative study: conventional cervical and ThinPrep Pap tests in routine clinical setting. Cytopatology 2002; 13 (4): 200-5.
  24. Hadwin R, Eggington S, Brennan A et al. Modelling the cost-effectiveness and capacity impact of changes to colposcopy referral guidelines for women with mild dyskaryosis in the UK Cervical Screening Programme. BJOG 2008; 115 (6): 749-57.
  25. Kim JJ, Wright TC, Goldie SJ. Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France and Italy. JNCI J Nat Cancer Inst 2005; 97: 888.
  26. Koliopoulos G, Arbyn M, Martin-Hirsch P et al. Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies. Gynecol Oncol 2007; 104: 232.
  27. Lee K, Ashfaq R, Birdsong G et al. Сomparison of conventional Papanicolaou smears and a fluid-based, thin-layer system for cervical cancer screening. Obstet Gynecol 1997; 90: 278-84.
  28. Mayrand MH, Duarte-Franco E, Rodrigues I et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007; 357 (16): 1579-88.
  29. Monsonego J, Autillo-Touati A, Bergeron C et al. Liquid-based cytology for primary cervical cancer'screening: a multi-centre study. Br J Cancer 2001; 84: 360-6.
  30. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74.
  31. Singer А, Coppleson M, Canfell K et al. A real time optoelectronic device as an adjunct to the Pap smear for cervical screening: A multicenter evaluation. Int J Gynecol Cancer 2003; 13 (6): 804-11.
  32. Sung Jong Lee, Jeong Hoon Bae, Jin Hwi Kim et al. A real-time optoelectronic device in screening of cervical intraepithelial neoplasia; Department of Obstetrics and Gynecology, School of Medicine, Catholic University, Seoul, Korea. J Women Med 2009; 1 (2).
  33. Valanis BG, Glasgow RE, Mullooly J et al. Screening HMO Women Overdue for both Mammograms and Pap Tests Prev Med 2002; 34 (1): 40-50.
  34. Wang T, Chen H, Yang Y, Tsou M. Comparison of fluid-based, thin-layer processing and conventional Papanicolaou methods for uterine cervical cytology. J Formos Med Assoc 1999; 98: 500-5.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС77-63961 от 18.12.2015.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies